Clinical Trials Logo

Disease clinical trials

View clinical trials related to Disease.

Filter by:

NCT ID: NCT05206734 Active, not recruiting - Schizophrenia Clinical Trials

Risk of Mental Health Conditions in Children and Young Adults With Inflammatory Bowel Disease and Influence on Health

Start date: January 5, 2022
Phase:
Study type: Observational

This study is a large population-based analysis in the United Kingdom (UK) using routine primary care data to investigate the risk of mental health conditions in children, adolescents and young adults with Inflammatory Bowel Disease, compared to those without Inflammatory Bowel Disease. The study will also compare the impacts on quality-of-life outcomes and use of healthcare services between people with Inflammatory Bowel Disease with and without mental health conditions.

NCT ID: NCT05206292 Not yet recruiting - Schizophrenia Clinical Trials

Estimating Prevalence of Inherited Disorders of Sulfur Amino Acids Metabolism in Patients With Psychotic Disorders.

PsyNIT
Start date: April 1, 2022
Phase: N/A
Study type: Interventional

Screening for sulfur amino acid metabolism pathologies using a sulfitest in adult patients with psychotic disorder.

NCT ID: NCT05204459 Recruiting - Multiple Sclerosis Clinical Trials

MS-ResearchBiomarkerS

MS-ReBS
Start date: November 11, 2021
Phase:
Study type: Observational

This study is being conducted to investigate risk factors for disability progression in Multiple Sclerosis and related disorders (MSRD). The primary goal is to assess whether combining information from visual assessment, blood markers, as well as historical and ongoing longitudinal MRIs of the brain, orbit (the part of the skull where eyes are located), and/or spinal cord can predict changes in quantitative disability measures related to MSRD and neurological disease.

NCT ID: NCT05204225 Not yet recruiting - Stroke Clinical Trials

Clinical Effectiveness of the ReHand App in Hand Rehabilitation After Stroke

Start date: January 17, 2022
Phase: N/A
Study type: Interventional

Stroke is the third leading cause of disability worldwide, being the hand one of the segments whose affectation generates the greatest limitation in functionality and quality of life. Neurorehabilitation is the most effective therapy as long as it is implemented both in the early (post-hospital stages) and in an intensive approach. However, the resources of healthcare systems are not enough to address the neurorehabilitation needs of these patients. This is why the scientific literature advocates the transfer of such rehabilitation to the patient's home through therapeutic exercise programs - whose clinical and economic effectiveness has already been demonstrated - as a way of reducing the consumption of resources. Thus, telerehabilitation is suggested as one of the most viable formats. However, current telerehabilitation systems such as video games and virtual reality do not provide a fully viable solution, mainly due to the lack of scalability and penetration of the technology, and the lack of a hand approach, whose importance is crucial in the recovery of functionality and autonomy in Activities of Daily Living (ADL). Different articles and reviews confirm the potential of tablet devices to solve these issues given their scalability and the multisensory feedback they provide, making possible a more productive and intensive motor training and sensory stimulation in order to optimize cortical reorganization and neuroplasticity after a stroke. The need for a Tablet application for neurorehabilitation of the hand that follows the precepts set by the evidence has been expressed by both health professionals and patients. However, the lack of specific applications for this approach means that existing apps are used as an adaptation. This is why it is proposed the creation and preliminary validation of ReHand, the first Tablet application developed following the needs of professionals and patients, and the precepts of the most updated scientific literature, allowing the patient to perform an active therapy adapted to his limitation, and the health professional to monitor his patient's home work.

NCT ID: NCT05203731 Not yet recruiting - Clinical trials for Generalized Anxiety Disorder

Level of Physical Activity and Fear Learning

Start date: March 15, 2022
Phase: N/A
Study type: Interventional

The proposed experimental study will be the first to investigate whether exercise vs. sitting enhances consolidation of extinction learning in adults with high AS and anxiety disorders, and the mechanistic pathways of expectancy, affect, and key stress response markers.

NCT ID: NCT05203341 Recruiting - Clinical trials for Major Depressive Disorder

Study to Assess the Efficacy and Safety of Adjunctive NBI-1065845 in Adults With Major Depressive Disorder (MDD)

SAVITRI
Start date: January 2022
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate the efficacy of NBI-1065845 compared with placebo used in addition to oral antidepressants in adults with MDD on improving symptoms of depression.

NCT ID: NCT05202223 Recruiting - Alzheimer Disease Clinical Trials

Harmony at Home: A Pilot Telehealth Program for Rural ADRD Caregivers

Start date: January 2022
Phase: N/A
Study type: Interventional

There is a need for caregiver-initiated and -implemented non-pharmacological interventions directly to and for the person with dementia, including environmental assessment and modification, as first-line treatments for behavioral and psychological symptoms of dementia (BPSD) in persons living with dementia (PLWD). Delivered via telehealth, Harmony at HOME ([email protected]) aims to train caregivers of persons with moderate to severe ADRD in the skills of assessing and modifying the home environment to promote "person-environment fit," a concept that posits that the ability to access features within a built environment (e.g. bathroom, stairs,) or that factors within the environment itself (lighting, noise level, temperature), especially when linked with individualized social support, contribute to or even shape behavior.

NCT ID: NCT05201534 Not yet recruiting - Child Development Clinical Trials

Interventions in Mathematics and Cognitive Skills

Start date: September 1, 2022
Phase: N/A
Study type: Interventional

The purpose of this study is to investigate neurocognitive mechanisms underlying response to intervention aimed at enhancing, and remediating weaknesses in, numerical skills in children, including those with mathematical learning disabilities (MLD).

NCT ID: NCT05195840 Not yet recruiting - Eating Disorders Clinical Trials

Personalized Treatment for Eating Disorders Versus CBT-E Trial

PT
Start date: May 1, 2022
Phase: N/A
Study type: Interventional

Our scientific premise, developed from our past work, is that treatment personalized based on idiographic models (termed Network Informed Personalized Treatment; NA-PT) will outperform the current gold-standard treatment (Enhanced Cognitive Behavioral Therapy: CBT-E). Our study goals are to (1) develop and test the acceptability, feasibility, and preliminary efficacy of a randomization of NA-PT versus CBT-E and (2) to test if network-identified precision targets are the mechanism of change. These goals will ultimately lead to the very first personalized treatment for ED and can be extended to additional psychiatric illnesses. Specific aims are (1) To collect preliminary data on the feasibility and acceptability of the randomization of NA-PT (n=40) for EDs versus CBT-E (n=40), (2) To test the initial clinical efficacy of NA-PT versus CBT-E on clinical outcomes (e.g., ED symptoms, body mass index, quality of life) and (3) To examine if changes in NA-identified, precision targets, as well as in dynamic network structure, are associated with change in clinical outcomes.

NCT ID: NCT05193318 Recruiting - Clinical trials for Major Depressive Disorder

KAP for Depression in Abstinent Opioid Users

KReDO
Start date: January 5, 2022
Phase: Phase 2
Study type: Interventional

The purpose of the study is to examine whether an investigational medication called ketamine along with psychotherapy is an effective treatment for depression in participants with a history of opioid addiction who have not abused opioids in at least 3 months. Participants will receive ketamine through intramuscular injection along with psychotherapy weekly for 8 weeks. Participation for eligible subjects who decide to enroll (including post-medication follow-up visits) will last about 16 weeks or 4 months.